Treatment of myelogenous leukemia: current status and investigational options

Blood. 1996 Apr 15;87(8):3069-81.

Authors

H M Kantarjian¹, S O'Brien, P Anderlini, M Talpaz

Affiliation

¹ Department of Hematology, M.D. Anderson Cancer Center Houston TX, 77030, USA.

PMID: 8605319

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Bone Marrow Transplantation
Cytarabine / therapeutic use
Harringtonines / therapeutic use
Hematopoietic Stem Cell Transplantation
Homoharringtonine
Humans
Immunologic Factors / therapeutic use
Interferon-alpha / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Prognosis
Randomized Controlled Trials as Topic
Remission Induction
Risk Factors
Salvage Therapy
Treatment Outcome

Substances

Antineoplastic Agents
Harringtonines
Immunologic Factors
Interferon-alpha
Cytarabine
Homoharringtonine